Efficacy and safety of <scp>iGlarLixi</scp> versus <scp>IDegAsp</scp> by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
iGlarLixi provides improved glycaemic control at lower insulin daily doses compared with IDegAsp, regardless of C-peptide or HOMA-β levels, in Chinese people with uncontrolled T2D on OADs.
Authors
- Yiming Mu (ORCID: https://orcid.org/0000-0002-3344-3540)
- Felipe Lauand
- Minlu Zhang (ORCID: https://orcid.org/0000-0003-2347-0569)
- Lei Kang (ORCID: https://orcid.org/0000-0002-6239-1727)
- Xiaohong Wu (ORCID: https://orcid.org/0000-0001-5984-3342)
- Weijun Gu (ORCID: https://orcid.org/0000-0001-8690-645X)
- Xinyi Wang (ORCID: https://orcid.org/0009-0002-6349-8013)
- Qin Du
- Agustina Alvarez
Institutions
- Chinese PLA General Hospital (CN)
- Sanofi (France) (FR)
- Sanofi (Spain) (ES)
- People's Liberation Army No. 150 Hospital (CN)
- Sanofi (China) (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1111/dom.70181
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00